SCHEMBL23196147

SCHEMBL23196147

CC(C)(C)OC(=O)NC[C@@](C)(O)c1cc2c(c(-c3ccc(F)cc3)n1)OC[C@]2(C)CO

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.38
CFTR P13569 3/20 0.35
LATS1 O95835 2/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CYP2C9 P11712 1/20 0.33
IDO1 P14902 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
MIF P14174 1/20 0.32
LATS2 Q9NRM7 1/20 0.32
SCN9A Q15858 2/20 0.32
BRD4 O60885 1/20 0.31
FPR2 P25090 1/20 0.31
RORC P51449 3/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
GRIA1 P42261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23196149 1.00 GRM2 (0.38) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL23196094 0.92 GRM2 (0.37) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL23905424 0.90 GRM2 (0.36) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL26537778 0.89 GRM2 (0.34) GRM2CFTRPDE3BPDE3AHDAC1
SCHEMBL23195598 0.89 GRM2 (0.34) GRM2CFTRPDE3BPDE3AHDAC1
SCHEMBL23196044 0.89 GRM2 (0.35) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL23195889 0.88 GRM2 (0.38) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL24985735 0.88 GRM2 (0.38) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL31412382 0.88 GRM2 (0.38) GRM2CFTRLATS1PDE3BPDE3A
SCHEMBL23905656 0.83 CFTR (0.37) GRM2CFTRLATS1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 US disclosed
WO-2021066922-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 GRM2 4163/4885CFTR 283/4885LATS1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.